We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+7.84%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$245M
AUM Growth
-$7.55M
Cap. Flow
+$6.28M
Cap. Flow %
2.56%
Top 10 Hldgs %
55.89%
Holding
90
New
18
Increased
14
Reduced
12
Closed
22

Top Buys

Rank Stock Value
1
SKYE icon
Skye Bioscience
SKYE
+$16M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$10.5M
3
ARGX icon
argenx
ARGX
+$8.8M
4
CTNM
Contineum Therapeutics
CTNM
+$6.91M
5
RZLT icon
Rezolute
RZLT
+$5.84M

Top Sells

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$7.66M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$6.85M
3
AXSM icon
Axsome Therapeutics
AXSM
+$6.52M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$5.22M
5
NGNE icon
Neurogene
NGNE
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 96.66%
2 Consumer Discretionary 1.68%
3 Technology 0.03%
4 Financials 0.01%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
26
Ultragenyx Pharmaceutical
RARE
$2.49B
$2.88M 1.17%
+70,000
New +$2.99M
ORIC icon
27
Oric Pharmaceuticals
ORIC
$1.24B
$2.86M 1.17%
405,000
– –
VERU icon
28
Veru
VERU
$37.7M
$1.92M 0.78%
227,669
+16,496
+8% +$191K
CATX icon
29
Perspective Therapeutics
CATX
$347M
$1.91M 0.78%
191,450
+137,884
+257% +$1.99M
LRMR icon
30
CALL
Larimar Therapeutics
LRMR
$409M
$1.42M 0.58%
+196,000
New +$1.5M
MIST icon
31
Milestone Pharmaceuticals
MIST
$143M
$1.34M 0.55%
1,012,368
-200,514
-17% -$322K
ACHV icon
32
Achieve Life Sciences
ACHV
$653M
$1.02M 0.41%
216,310
-619,160
-74% -$2.98M
ALUR
33
DELISTED
Allurion Technologies
ALUR
$968K 0.39%
+38,794
New +$1.79M
ANVS icon
34
PUT
Annovis Bio
ANVS
$74M
$895K 0.36%
+155,300
New +$1.26M
BIVI icon
35
BioVie
BIVI
$12.1M
$794K 0.32%
19,823
-10,303
-34% -$493K
CNTX icon
36
Context Therapeutics
CNTX
$57.4M
$722K 0.29%
+360,001
New +$621K
KPTI icon
37
Karyopharm Therapeutics
KPTI
$45.3M
$642K 0.26%
49,333
– –
RAPT
38
CALL
DELISTED
RAPT Therapeutics
RAPT
$610K 0.25%
25,000
– –
FATBW
39
DELISTED
FAT Brands Inc. Warrant
FATBW
$569K 0.23%
200,000
– –
APRE icon
40
Aprea Therapeutics
APRE
$7.47M
$558K 0.23%
+137,197
New +$707K
SPRB
41
Spruce Biosciences
SPRB
$123M
$420K 0.17%
10,816
-4,517
-29% -$242K
EVOK
42
DELISTED
Evoke Pharma
EVOK
$366K 0.15%
57,703
-2,709
-4% -$16.3K
BOLD
43
Boundless Bio
BOLD
$58M
$322K 0.13%
83,149
-116,851
-58% -$1.12M
LXRX icon
44
Lexicon Pharmaceuticals
LXRX
$1.06B
$205K 0.08%
+121,986
New +$219K
INBS icon
45
Intelligent Bio Solutions
INBS
$4.23M
$161K 0.07%
+8,391
New +$215K
PMNT
46
DELISTED
PERFECT MOMENT LTD
PMNT
$135K 0.06%
62,835
-29,373
-32% -$83.8K
NXGLW icon
47
NexGel Inc Warrant
NXGLW
$98.3K 0.04%
225,000
– –
SVRA icon
48
CALL
Savara
SVRA
$1.11B
$80.6K 0.03%
+20,000
New +$89K
CETX icon
49
Cemtrex
CETX
$4.6M
$74.8K 0.03%
+1
New +$394K
WLDSW icon
50
Wearable Devices Ltd Warrant
WLDSW
$70K 0.03%
1,961
– –
1
2
3 4

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
LSA
Liberty Street Advisors New York $41.4M AUM 34.47% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
GC
Gruss & Co West Palm Beach, Florida $42.8M AUM 49.41% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return

Altium Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Altium Capital Management held 90 positions worth $245M, down 3% from $253M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Altium Capital Management's Q2 2024 filing shows 18 new, 14 increased, 12 reduced and 22 closed positions. Its largest new stake was Skye Bioscience: 1,350,093 shares worth $10.8M. The largest sale was Biohaven, an estimated $7.66M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 86% a quarter earlier, followed by Consumer Discretionary and Technology.

  • Altium Capital Management's largest Q2 2024 buy was Skye Bioscience: 1,350,093 shares worth $10.8M.
  • Altium Capital Management added most to Intra-Cellular Therapies Inc. in Q2 2024, an estimated $5.55M increase.
  • Altium Capital Management's biggest Q2 2024 reduction was Axsome Therapeutics, cutting an estimated $6.52M.
  • Altium Capital Management fully exited Biohaven in Q2 2024, selling an estimated $7.66M.
  • Altium Capital Management's ten largest holdings make up 56% of its $245M portfolio in Q2 2024.
  • Altium Capital Management opened 18 new positions and closed 22 in Q2 2024.
  • Altium Capital Management's portfolio value fell 3% quarter-over-quarter to $245M.

Based on Altium Capital Management's 13F filing for Q2 2024, filed 15 Aug 2024.